BSE Live
Nov 17, 16:01Prev. Close
945.20
Open Price
948.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 17, 15:49Prev. Close
943.55
Open Price
951.00
Bid Price (Qty.)
948.75 (95)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Strides Pharma Science (in Rs. Cr.) | Dec 09 | Dec 08 | Dec 07 | Dec 06 | Dec 05 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 27.27 | 26.96 | -14.32 | 11.51 | 13.89 | |
| Diluted EPS (Rs.) | 27.27 | 26.96 | -14.32 | 11.51 | 13.89 | |
| Cash EPS (Rs.) | 42.35 | 35.99 | -3.98 | 23.69 | 22.71 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 255.19 | 136.46 | 64.39 | 99.04 | 81.11 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 255.19 | 136.46 | 64.39 | 99.04 | 81.11 | |
| Revenue from Operations/Share (Rs.) | 324.41 | 254.71 | 207.04 | 212.56 | 149.76 | |
| PBDIT/Share (Rs.) | 56.53 | 46.61 | 33.22 | 38.65 | 31.02 | |
| PBIT/Share (Rs.) | 44.30 | 36.65 | 22.83 | 29.80 | 25.00 | |
| PBT/Share (Rs.) | 27.34 | 17.39 | 5.55 | 19.04 | 16.94 | |
| Net Profit/Share (Rs.) | 30.10 | 25.99 | -14.76 | 14.07 | 15.96 | |
| NP After MI And SOA / Share (Rs.) | 27.27 | 26.96 | -14.32 | 11.51 | 13.89 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 17.42 | 18.29 | 16.04 | 18.18 | 20.71 | |
| PBIT Margin (%) | 13.65 | 14.38 | 11.02 | 14.02 | 16.69 | |
| PBT Margin (%) | 8.42 | 6.82 | 2.67 | 8.95 | 11.31 | |
| Net Profit Margin (%) | 9.27 | 10.20 | -7.12 | 6.61 | 10.66 | |
| NP After MI And SOA Margin (%) | 8.40 | 10.58 | -6.91 | 5.41 | 9.27 | |
| Return on Networth/Equity (%) | 14.28 | 29.47 | -24.04 | 13.70 | 19.63 | |
| Return on Capital Employed (%) | 4.90 | 6.65 | -3.65 | 4.52 | 6.96 | |
| Return on Assets (%) | 3.39 | 4.63 | -2.46 | 3.27 | 5.18 | |
| Total Debt/Equity (X) | 1.90 | 3.55 | 6.13 | 1.88 | 1.77 | |
| Asset Turnover Ratio (%) | 40.39 | 43.83 | 35.64 | 60.55 | 55.92 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.95 | 1.06 | 1.11 | 1.40 | 1.77 | |
| Quick Ratio (X) | 0.72 | 0.82 | 0.81 | 1.04 | 1.40 | |
| Inventory Turnover Ratio (X) | 5.59 | 5.89 | 3.60 | 6.03 | 6.00 | |
| Dividend Payout Ratio (NP) (%) | 5.49 | 0.00 | -0.03 | 17.37 | 14.39 | |
| Dividend Payout Ratio (CP) (%) | 3.79 | 0.00 | -0.13 | 9.46 | 9.68 | |
| Earnings Retention Ratio (%) | 94.51 | 0.00 | 100.03 | 82.63 | 85.61 | |
| Cash Earnings Retention Ratio (%) | 96.21 | 0.00 | 100.13 | 90.54 | 90.32 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 2.61 | 1.90 | 1.32 | 2.77 | 3.10 | |
| Interest Coverage Ratios (Post Tax) (%) | 2.61 | 1.90 | 1.32 | 2.77 | 3.10 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 2,635.28 | 1,832.75 | 2,141.11 | 1,896.42 | 1,512.31 | |
| EV/Net Operating Revenue (X) | 2.02 | 1.80 | 2.95 | 2.55 | 2.89 | |
| EV/EBITDA (X) | 11.59 | 9.82 | 18.41 | 14.04 | 13.95 | |
| MarketCap/Net Operating Revenue (X) | 0.74 | 0.35 | 1.37 | 1.72 | 2.07 | |
| Retention Ratios (%) | 94.50 | 0.00 | 100.03 | 82.62 | 85.60 | |
| Price/BV (X) | 1.25 | 0.98 | 4.75 | 4.36 | 4.38 | |
| Price/Net Operating Revenue | 0.74 | 0.35 | 1.37 | 1.72 | 2.07 | |
| Earnings Yield | 0.11 | 0.30 | -0.05 | 0.03 | 0.04 |
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
09.09.2025
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
29.07.2025
Strides Pharma Consolidated June 2025 Net Sales at Rs 1,119.74 crore, up 2.96% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016